Application of data mining approaches to drug delivery

Advanced Drug Delivery Reviews

Volumn 58, Issue 12-13, 2006, Pages 1409-1430

  Ekins, Sean ^a,b   Shimada, Jun ^c   Chang, Cheng ^b  

^a ACT LLC   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Data mining; Databases; Drug delivery; Modeling; Networks; Pharmacophore; Predictions; QSAR; Systems biology; Transporters

Indexed keywords

COMPUTATIONAL METHODS; COMPUTER SOFTWARE; CONTROLLED DRUG DELIVERY; DATA ACQUISITION; DATABASE SYSTEMS; DRUG PRODUCTS PLANTS; LEARNING SYSTEMS;

DATA VISUALIZATION; DECISION TREES; PHARMACOPHORE; QSAR; SYSTEMS BIOLOGY;

DATA MINING;

ALGORITHM; ARTIFICIAL NEURAL NETWORK; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG DELIVERY SYSTEM; DRUG RESEARCH; GENOMICS; INFORMATION PROCESSING; PHARMACOPHORE; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; DRUG INTERACTIONS; HUMANS; MODELS, MOLECULAR; PEPTIDE MAPPING; STATISTICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33751249304     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.09.005     Document Type: Review

References (153)

1. Nwaka S., and Ridley R.G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov. 2 (2003) 919-928
2. Pritchard J.F., Jurima-Romet M., Reimer M.L., Mortimer E., Rolfe B., and Cayen M.N. Making better drugs: decision gates in non-clinical drug development. Nat. Rev. Drug Discov. 2 (2003) 542-553
3. Ekins S., and Swaan P.W. Computational models for enzymes, transporters, channels and receptors relevant to absorption, distribution, metabolism, excretion and toxicology. Rev. Comput. Chem. 20 (2004) 333-415
4. Lloyd D.G., Golfis G., Knox A.J.S., Fayne D., Meegan M.J., and Oprea T.I. Oncology exploration: chartering cancer medicinal chemistry space. DDT 11 (2006) 149-159
5. Ekins S., de Groot M., and Jones J.P. Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. 29 (2001) 936-944
6. Ekins S., Berbaum J., and Harrison R.K. Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab. Dispos. 31 (2003) 1077-1080
7. Jorgensen W.L. The many roles of computation in drug discovery. Science 303 (2004) 1813-1818
8. Cheng A., Diller D.J., Dixon S.L., Egan W.J., Lauri G., and Merz Jr. K.M.J. Computation of the physico-chemical properties and data mining of large molecular collections. J. Comput. Chem. 23 (2002) 172-183
9. Lengauer T., Lemmen C., Rarey M., and Zimmermann M. Novel technologies for virtual screening. Drug Discov. Today 9 (2004) 27-34
10. Manly C.J., Louise-May S., and Hammer J.D. The impact of informatics and computational chemistry on synthesis and screening. Drug Discov. Today 6 (2001) 1101-1110
11. Engels M.F.M., and Venkatarangan P. Smart screening: approaches to efficient HTS. Curr. Opin. Drug Discov. Dev. 4 (2001) 275-283
12. Ekins S. Computer Applications in Pharmaceutical Research and Development (2006), John Wiley and Sons, Hoboken
13. Ekins S., Waller C.L., Swaan P.W., Cruciani G., Wrighton S.A., and Wikel J.H. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods 44 (2000) 251-272
14. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E., Lan L.-B., Yasuda K., Shepard R.L., Winter M.A., Schuetz J.D., Wikel J.H., and Wrighton S.A. Application of three dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61 (2002) 974-981
15. Ekins S., Stresser D.M., and Williams J.A. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 24 (2003) 161-166
16. Zhang E.Y., Knipp G.T., Ekins S., and Swaan P.W. Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab. Rev. 34 (2002) 709-750
17. Zhang E.Y., Phelps M.A., Cheng C., Ekins S., and Swaan P.W. Modeling of active transport systems. Adv. Drug Deliv. Rev. 54 (2002) 329-354
18. Bednarczyk D., Ekins S., Wikel J.H., and Wright S.H. Influence of molecular structure of substrate binding to the human organic cation transporter, hOCT1. Mol. Pharmacol. 63 (2003) 489-498
19. Ekins S., Kirillov E., Rakhmatulin E., and Nikolskaya T. A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab. Dispos. 33 (2005) 474-481
20. Ivanenkov Y.A., Balakin K.V., Savchuk N.P., and Nikolsky Y. Design of ion channel-targeted libraries using unsupervised machine learning approach. Intelligent Drug Discovery and Development, Philadelphia (2003) 27-30
21. Rawlins M.D. Cutting the cost of drug development?. Nat. Rev. Drug Discov. 3 (2004) 360-364
22. Ekins S., Boulanger B., Swaan P.W., and Hupcey M.A.Z. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput. Aided Mol. Des. 16 (2002) 381-401
23. Bugrim A., Nikolskaya T., and Nikolsky Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov. Today 9 (2004) 127-135
24. Lanfear J. Dealing with the data deluge. Nat. Rev. Drug Disc. 1 (2002) 479
25. Navarro J.D., Niranjan V., Peri S., Jonnalagadda C.K., and Pandey A. From biological databases to platforms for biomedical discovery. Trends Biotechnol. 21 (2003) 263-268
26. Bourne P. Will a biological database be different from a biological journal?. PLoS Comput. Biol. 1 (2005) 179-181
27. Block P., Sotriffer C.A., Dramburg I., and Klebe G. AffinDB: a freely accessible database of affinities for protein-ligand complexes from the PDB. Nucleic Acids Res. 34 (2006) D522-D526
28. Ng A., Bursteinas B., Gao Q., Mollison E., and Zvelebil M. pSTIING: a 'systems' approach towards integrating signalling pathways, interaction and transcriptional regulatory networks in inflammation and cancer. Nucleic Acids Res. 34 (2006) D527-D534
29. Navia M.A., and Chaturvedi P.R. Design principles for orally bioavailable drugs. Drug Discov. Today 1 (1996) 179-189
30. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
31. Lipinski C.A. Avoiding investment in doomed drugs is poor solubility an industry wide problem?. Curr. Drug Discov. (April 2001) 17-19
32. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
33. Lipinski C.A. Filtering in drug discovery. Annu. Rep. Comput. Chem. 1 (2005) 155-168
34. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303 (2002) 1029-1037
35. Norinder U., and Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Deliv. Rev. 54 (2002) 291-313
36. Allen D.D., and Geldenhuys W.J. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci. 78 (2006) 1029-1033
37. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
38. Crivori P., Cruciani G., Carrupt P.A., and Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43 (2000) 2204-2216
39. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Disc. 1 (2002) 727-730
40. Kubinyi H. Drug Research: myths, hype and reality. Nat. Rev. Drug Disc. 2 (2003) 665-668
41. Kauvar L.M., Villar H.O., Sportsman J.R., Higgins D.L., and Schmidt D.E.J. Protein affinity map of chemical space. J. Chromatogr., B, Biomed. Sci. Appl. 715 (1998) 93-102
42. Kauvar L.M., Higgins D.L., Villar H.O., Sportsman J.R., Engqvist-Goldstein A., Bukar R., Bauer K.E., Dilley H., and Rocke D.M. Predicting ligand binding to proteins by affinity fingerprinting. Chem. Biol. 2 (1995) 107-118
43. Horvath D., and Jeandenans C. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces-a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. J. Chem. Inf. Comput. Sci. 43 (2003) 680-690
44. Fliri A.F., Loging W.T., Thadeio P.F., and Volkmann R.A. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. J. Med. Chem. 48 (2005) 6918-6925
45. Fliri A.F., Loging W.T., Thadeio P.F., and Volkmann R.A. Biological spectra analysis: linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 261-266
46. Fliri A.F., Loging W.T., Thadeio P.F., and Volkmann R.A. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol. 1 (2005) 389-397
47. Ekins S. Systems-ADME/Tox: resources and network approaches. J. Pharmacol. Toxicol. Methods 53 (2006) 38-66
48. Shorter E. Looking backwards: a possible new path for drug discovery in psychopharmacology. Nat. Rev. Drug Disc. 1 (2002) 1003-1006
49. Ekins S., Bugrim A., Nikolsky Y., and Nikolskaya T. Systems biology: applications in drug discovery. In: Gad S.C. (Ed). Drug Discovery Handbook (2005), Wiley, New York 123-183
50. Roth B.L., Lopez E., Beischel S., Westkaemper R.B., and Evans J.M. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol. Ther. 102 (2004) 99-110
51. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., McKee D.D., Oliver B.B., Willson T.M., Zetterstrom R.H., Perlmann T., and Lehmann J.M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell 92 (1998) 73-82
52. Nakata K., Yukawa M., Komiyama N., Nakano T., and Kaminuma T. A nuclear receptor database that maps pathways to diseases. Genome Inf. 13 (2002) 515-516
53. Sun L.Z., Ji Z.L., Chen X., Wang J.F., and Chen Y.Z. ADME-AP: a database of ADME associated proteins. Bioinformatics 18 (2002) 1699-1700
54. Yan Q., and Sadee W. Human membrane transporter database: a web-accessible relational database for drug transport studies and pharmacogenomics. AAPS PharmSci 2 (2000) E20
55. Schapira M., Raaka B.M., Samuels H.H., and Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1008-1013
56. Ozawa N., Shimizu T., Morita R., Yokono Y., Ochiai T., Munesada K., Ohashi A., Aida Y., Hama Y., Taki K., Maeda K., Kusuhara H., and Sugiyama Y. Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res. 21 (2004) 2133-2134
57. Saier Jr. M.H., Tran C.V., and Barabote R.D. TCDB: the Transporter Classification Database for membrane transport protein analyses and information. Nucleic Acids Res. 34 (2006) D181-D186
58. Chang C., Pang K.S., Swaan P.W., and Ekins S. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and OATP1B1. J. Pharmacol. Exp. Ther. 314 (2005) 533-541
59. Sahi J., Sinz M.W., Campbell S., Mireles R., Zheng X., Rose K.A., Raeissi S., Hashim M.F., Ye Y., de Morais S.M., Black C., Tugnait M., and Keller L.H. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem.-Biol. Interact. 159 (2006) 156-168
60. Ganter B., Tugendreich S., Pearson C.I., Ayanoglu E., Baumhueter S., Bostian K.A., Brady L., Browne L.J., Calvin J.T., Day G.J., Breckenridge N., Dunlea S., Eynon B.P., Furness L.M., Ferng J., Fielden M.R., Fujimoto S.Y., Gong L., Hu C., Idury R., Judo M.S., Kolaja K.L., Lee M.D., McSorley C., Minor J.M., Nair R.V., Natsoulis G., Nguyen P., Nicholson S.M., Pham H., Roter A.H., Sun D., Tan S., Thode S., Tolley A.M., Vladimirova A., Yang J., Zhou Z., and Jarnagin K. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J. Biotechnol. 119 (2005) 219-244
61. Castle A.L., Carver M.P., and Mendrick D.L. Toxicogenomics: a new revolution in drug safety. Drug Discov. Today 7 (2002) 728-736
62. Perou C.M. Show me the data!. Nat. Genet. 29 (2001) 373
63. Waters M., Boorman G., Bushel P., Cunningham M., Irwin R., Merrick A., Olden K., Paules R., Selkirk J., Stasiewicz S., Weis B., Van Houten B., Walker N., and Tennant R. Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. EHP Toxicogenomics 111 (2003) 15-28
64. Mattes W.B., Pettit S.D., Sansone S.A., Bushel P.R., and Waters M.D. Database development in toxicogenomics: issues and efforts. Environ. Health Perspect. 112 (2004) 495-505
65. Xirasagar S., Gustafson S.F., Huang C.C., Pan Q., Fostel J., Boyer P., Merrick B.A., Tomer K.B., Chan D.D., Yost III K.J., Choi D., Xiao N., Stasiewicz S., Bushel P., and Waters M.D. Chemical effects in biological systems (CEBS) object model for toxicology data, SysTox-OM: design and application. Bioinformatics 22 (2006) 874-882
66. Romiti N., Tongiani R., Cervelli F., and Chieli E. Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci. 62 (1998) 2349-2358
67. Rowley M., Hallett D.J., Goodacre S., Moyes C., Crawforth J., Sparey T.J., Patel S., Marwood R., Thomas S., Hitzel L., O'Connor D., Szeto N., Castro J.L., Hutson P.H., and MacLeod A.M. 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J. Med. Chem. 44 (2001) 1603-1614
68. Hackett J.L., and Lesko L.J. Microarray data- the US FDA, industry and academia. Nat. Biotechnol. 21 (2003) 742-743
69. Shoichet B.K. Virtual screening of chemical libraries. Nature 432 (2004) 862-865
70. Martin Y.C. 3D database searching in drug design. J. Med. Chem. 35 (1992) 2145-2154
71. Martin Y.C., Bures M.G., Danaher E.A., DeLazzer J., Lico I., and Pavlik P.A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput.-Aided Mol. Des. 7 (1993) 83-102
72. Barnum D., Greene J., Smellie A., and Sprague P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 36 (1996) 563-571
73. Sprague P.W. Automated chemical hypothesis generation and database searching with Catalyst. Perspect. Drug Discov. Des. 3 (1995) 1-20
74. Sprague P.W., and Hoffman R. CATALYST pharmacophore models and their utility as queries for searching 3D databases. In: van de Waterbeemd H., Testa B., and Folkers G. (Eds). Computer-assisted Lead Finding and Optimization (1997), Verlag Helvetica Chimica Acta, Basel 225-240
75. Kaminski J.J., Rane D.F., Snow M.E., Weber L., Rothofsky M.L., Anderson S.D., and L.S.L. Identification of novel farnesyl protein transferase inhibitors using three-dimensional searching methods. J. Med. Chem. 40 (1997) 4103-4112
76. Wang S., Zaharevitz D.W., Sharma R., Marquez V.E., Lewin N.E., Du L., Blumberg P.M., and Milne G.W.A. The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database pharmacophore search. Molecular modeling studies. J. Med. Chem. 37 (1994) 4479-4489
77. Nicklaus M.C., Neamati N., Hong H., Mazumder A., Sunder S., Chen J., Milne G.W.A., and Pommier Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 40 (1997)
78. Chang C., and Swaan P.W. Computational approaches to modeling drug transporters. Eur. J. Pharm. Sci. 27 (2005) 411-424
79. de Graaf C., Vermeulen N.P., and Feenstra K.A. Cytochrome P450 in silico: an integrative modeling approach. J. Med. Chem. 48 (2005) 2725-2755
80. Egan W.J., Merz K.M.J., and Baldwin J.J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43 (2000) 3867-3877
81. Norinder U., Osterberg T., and Artursson P. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parameterization and PLS statistics. Eur. J. Pharm. Sci. 8 (1999) 49-56
82. Oprea T.I., and Gottfries J. Toward a minimalistic modeling of oral drug absorption. J. Mol. Graph. Model. 17 (1999) 261-274
83. Raevsky O.A., Schaper K.-J., Artursson P., and McFarland J.W. A novel approach for prediction of intestinal absorption of drugs in humans based on hydrogen bond descriptors and structural similarity. Quant. Struct.- Act. Relat. 20 (2001) 402-413
84. Stenberg P., Norinder U., Luthman K., and Artursson P. Experimental and computational screening models for the prediction of intestinal drug absorption. J. Med. Chem. 44 (2001) 1927-1937
85. Sugawara M., Takekuma Y., Yamada H., Kobayashi M., Iseki K., and Miyazaki K. A general approach for the prediction of the intestinal absorption of drugs: regression analysis using the physiochemical properties and drug-membrane electrostatic interaction. J. Pharm. Sci. 87 (1998) 960-966
86. Wessel M.D., Jurs P.C., Tolan J.W., and Muskal S.M. Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 38 (1998) 726-735
87. Niwa T. Using general regression and probabilistic neural networks to predict human intestinal absorption with topological descriptors derived from two-dimensional chemical structures. J. Chem. Inf. Comput. Sci. 43 (2003) 113-119
88. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88 (1999) 815-821
89. Karande P., Jain A., Ergun K., Kispersky V., and Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4688-4693
90. Ekins S., and Swaan P.W. Development of computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX. Rev. Comput. Chem. 20 (2004) 333-415
91. Ekins S., and Rose J.P. In Silico ADME/TOX: the state of the art at the 220th ACS meeting. J. Mol. Graph. 20 (2002) 305-309
92. Johnson J.A., Herring V.L., Wolfe M.S., and Relling M.V. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J. Pharmacol. Exp. Ther. 294 (2000) 1099-1105
93. Chang C., Ekins S., and Swaan P. Application of P-gp pharmacophore models in database screening. 229th ACS National Meeting, San Diego (2005) 509
94. Langer T., Eder M., Hoffmann R.D., Chiba P., and Ecker G.F. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch. Pharm. (Weinheim) 337 (2004) 317-327
95. Pleban K., Kaiser D., Kopp S., Peer M., Chiba P., and Ecker G.F. Targeting drug-efflux pumps - a pharmacoinformatic approach. Acta Biochim. Pol. 52 (2005) 737-740
96. Enyedy I.J., Sakamuri S., Zaman W.A., Johnson K.M., and Wang S. Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. Bioorg. Med. Chem. Lett. 13 (2003) 513-517
97. Enyedy I.J., Zaman W.A., Sakamuri S., Kozikowski A.P., Johnson K.M., and Wang S. Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors. Bioorg. Med. Chem. Lett. 11 (2001) 1113-1118
98. Wang S., Sakamuri S., Enyedy I.J., Kozikowski A.P., Deschaux O., Bandyopadhyay B.C., Tella S.R., Zaman W.A., and Johnson K.M. Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J. Med. Chem. 43 (2000) 351-360
99. Hoffman B.T., Kopajtic T., Katz J.L., and Newman A.H. 2D QSAR modeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors. J. Med. Chem. 43 (2000) 4151-4159
100. Groneberg D.A., Fischer A., Chung K.F., and Daniel H. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am. J. Respir. Cell Mol. Biol. 30 (2004) 251-260
101. van der Deen M., de Vries E.G., Timens W., Scheper R.J., Timmer-Bosscha H., and Postma D.S. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir. Res. 6 (2005) 59
102. Lips K.S., Volk C., Schmitt B.M., Pfeil U., Arndt P., Miska D., Ermert L., Kummer W., and Koepsell H. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am. J. Respir. Cell Mol. Biol. 33 (2005) 79-88
103. Hagenbuch B., and Meier P.J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609 (2003) 1-18
104. Pulaski L., Kania K., Ratajewski M., Uchiumi T., Kuwano M., and Bartosz G. Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J. Steroid Biochem. Mol. Biol. 96 (2005) 229-234
105. Zimmermann N., King N.E., Laporte J., Yang M., Mishra A., Pope S.M., Muntel E.E., Witte D.P., Pegg A.A., Foster P.S., Hamid Q., and Rothenberg M.E. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Invest. 111 (2003) 1863-1874
106. King N.E., Rothenberg M.E., and Zimmermann N. Arginine in asthma and lung inflammation. J. Nutr. 134 (2004) 2830S-2836S (discussion 2853S)
107. Li J.Y., Boado R.J., and Pardridge W.M. Blood-brain barrier genomics. J. Cereb. Blood Flow Metab. 21 (2001) 61-68
108. Rowe R.C., and Colbourn E. Computers in pharmaceutical formulation. In: Ekins S. (Ed). Computer Applications in Pharmaceutical Research and Development (2006), John Wiley and Sons, Hoboken 679-702
109. Metullio L., Ferrone M., Coslanich A., Fuchs S., Fermeglia M., Paneni M.S., and Pricl S. Polyamidoamine (Yet Not PAMAM) dendrimers as bioinspired materials for drug delivery: structure-activity relationships by molecular simulations. Biomacromolecules 5 (2004) 1371-1378
110. Lord P.G. Progress in applying genomics in drug development. Toxicol. Lett. 149 (2004) 371-375
111. Walgren J.L., and Thompson D.C. Application of proteomic technologies in the drug development process. Toxicol. Lett. 149 (2004) 377-385
112. Anderson N.L., and Anderson N.G. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19 (1998) 1853-1861
113. Klein J.B., and Thongboonkerd V. Overview of proteomics. Contrib. Nephrol. 141 (2004) 1-10
114. Heijne W.H., Slitt A.L., van Bladeren P.J., Groten J.P., Klaassen C.D., Stierum R.H., and van Ommen B. Bromobenzene-induced hepatotoxicity at the transcriptome level. Toxicol. Sci. 79 (2004) 411-422
115. Ruepp S.U., Tonge R.P., Shaw J., Wallis N., and Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 65 (2002) 135-150
116. Fountoulakis M., de Vera M.C., Crameri F., Boess F., Gasser R., Albertini S., and Suter L. Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol. Appl. Pharmacol. 183 (2002) 71-80
117. Barabasi A.-L., and Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat. Rev., Genet. 5 (2004) 101-113
118. Ekins S., Nikolsky Y., and Nikolskaya T. Techniques: application of systems biology to absorption, distribution, metabolism, excretion, and toxicity. Trends Pharmacol. Sci. 26 (2005) 202-209
119. Ekins S., Nikolsky Y., Bugrim A., Kirillov E., and Nikolskaya T. Pathway mapping tools for analysis of high content data. In: Giuliano K., Taylor D.L., and Haskin J. (Eds). High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery (2006), Humana Press, Totowa, NJ
120. Ekins S., Kirillov E., Rakhmatulin E.A., and Nikolskaya T. A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab. Dispos. 33 (2005) 474-481
121. S. Ekins, A. Bugrim, Y. Nikolsky, T. Nikolskaya, Systems biology: applications in drug discovery, in: S. Gad (Ed.), Drug discovery handbook, Wiley, New York, 2005, pp. 123-183.
122. S. Ekins, A. Bugrim, L. Brovold, E. Kirillov, Y. Nikolsky, E.A. Rakhmatulin, S. Sorokina, A. Ryabov, T. Serebryiskaya, A. Melnikov, J. Metz, T. Nikolskaya, Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms, Xenobiotica (in press).
123. Ekins S., and Giroux C. Computers and systems biology for Pharmaceutical Research and Development. In: Ekins S. (Ed). Computer Applications in Pharmaceutical Research and Development (2006), John Wiley and Sons, Hoboken 139-165
124. Wodak S.J., Castura J., and Orsi C. Integrative bioinformatics: making sense of the networks. Drug Discov. Today: Technol. 1 (2004) 179-187
125. Saraiya P., North C., and Duca K. Visualizing biological pathways: requirements anlysis, systems evaluation and research agenda. Inf. Vis. 1 (2005) 1-15
126. Ekins S., Andreyev S., Rybadov A., Kirillov E., Rakhmatulin E.A., Sorokina S., Bugrim A., and Nikolskaya T. A Combined Approach to Drug Metabolism and Toxicity Assessment. Drug Metab. Dispos. 34 (2006) 495-503
127. Ulrich R.G. The toxicogenomics of nuclear receptor agonists. Curr. Opin. Chem. Biol. 7 (2003) 505-510
128. Ulrich R., and Friend S.H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs?. Nat. Rev. Drug Discov. 1 (2002) 84-88
129. Sonoda J., Rosenfeld J.M., Xu L., Evans R.M., and Xie W. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. Curr. Drug Metab. 4 (2003) 59-72
130. Ekins S., Mirny L., and Schuetz E.G. A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRa and LXRb. Pharm. Res. 19 (2002) 1788-1800
131. Ueda A., Hamadeh H.K., Webb H.K., Yamamoto Y., Sueyoshi T., Afshari C.A., Lehmann J.M., and Negishi M. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. 61 (2002) 1-6
132. Rosenfeld J.M., Vargas Jr. R., Xie W., and Evans R.M. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol. Endocrinol. 17 (2003) 1268-1282
133. Tugwood J.D., and Montague C.T. Biology and toxicology of PPARgamma ligands. Hum. Exp. Toxicol. 21 (2002) 429-437
134. Yamazaki K., Kuromitsu J., and Tanaka I. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists. Biochem. Biophys. Res. Commun. 290 (2002) 1114-1122
135. Johnson C.D., Balagurunathan Y., Tadesse M.G., Falahatpisheh M.H., Brun M., Walker M.K., Dougherty E.R., and Ramos K.S. Unraveling gene-gene interactions regulated by ligands of the aryl hydrocarbon receptor. Environ. Health Perspect. 112 (2004) 403-412
136. Hartley D.P., Dai X., He Y.D., Carlini E.J., Wang B., Huskey S.E., Ulrich R.G., Rushmore T.H., Evers R., and Evans D.C. Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression. Mol. Pharmacol. 65 (2004) 1159-1171
137. Ekins S., Andreyev S., Ryabov A., Kirillov E., Rakhmatulin E.A., Sorokina S., Bugrim A., and Nikolskaya T. A combined approach to drug metabolism and toxicity assessment. Drug Metab. Dispos. 34 (2006) 495-503
138. Ekins S. Systems-ADME/Tox: resources and network approaches. J. Pharmacol. Toxicol. Methods 53 (2006) 38-66
139. Sharan R., and Ideker T. Modeling cellular machinery through biological network comparison. Nat. Biotechnol. 24 (2006) 427-433
140. Weininger D. SMILES 1. Introduction and encoding rules. J. Chem. Inf. Comput. Sci. 28 (1988) 31
141. Wang N., DeLisle R.K., and Diller D.J. Fast small molecule similarity searching with multiple alignment profiles of molecules represented in one-dimension. J. Med. Chem. 48 (2005) 6980-6990
142. Cvetkovic D., Rowlinson P., and Simic S. Eigenspaces of Graphs (1997), Cambridge University Press, Cambridge
143. Ahlberg C. Visual exploration of HTS databases: bridging the gap between chemistry and biology. Drug Discov. Today 4 (1999) 370-376
144. Stoner C.L., Gifford E., Stankovic C., Lepsy C.S., Brodfuehrer J., Prasad J.V., and Surendran N. Implementation of an ADME enabling selection and visualization tool for drug discovery. J. Pharm. Sci. 93 (2004) 1131-1141
145. Rojnuckarin A., Gschwend D.A., Rotstein S.H., and Hartsough D.S. ArQiologist: an integrated decision support tool for lead optimization. J. Chem. Inf. Model. 45 (2005) 2-9
146. Oellien F., Ihlenfeldt W.D., and Gasteiger J. InfVis-platform-independent visual data mining of multidimensional chemical data sets. J. Chem. Inf. Model. 45 (2005) 1456-1467
147. Bhasi K., Zhang L., Brazeau D., Zhang A., and Ramanathan M. VizStruct for visualization of genome-wide SNP analyses. Bioinformatics 22 (2006) 1569-1576
148. Kibbey C., and Calvet A. Molecular Property eXplorer: a novel approach to visualizing SAR using tree-maps and heatmaps. J. Chem. Inf. Model. 45 (2005) 523-532
149. Yamashita F., Itoh T., Hara H., and Hashida M. Visualization of large-scale aqueous solubility data using a novel hierarchical data visualization technique. J. Chem. Inf. Model. 46 (2006) 1054-1059
150. Balakin K.V., Ivanenkov Y.A., Savchuk N.P., Ivaschenko A.A., and Ekins S. Comprehensive computational assessment of ADME properties using mapping techniques. Curr. Drug Discov. Technol. 2 (2005) 99-113
151. Maniyar D.M., Nabney I.T., Williams B.S., and Sewing A. Data visualization during the early stages of drug discovery. J. Chem. Inf. Model. 46 (2006) 1806-1818
152. Tatsumi M., Groshan K., Blakely R.D., and Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340 (1997) 249-258
153. Tatsumi M., Jansen K., Blakely R.D., and Richelson E. Pharmacological profile of neuroleptics at human monomaine transporters. Eur. J. Pharmacol. 368 (1999) 277-283